Skip Navigation

European Heart Journal 2003 24(18):1699; doi:10.1016/S0195-668X(03)00369-5
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thimme, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thimme, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letters to the Editor

Lack of a rationale for the Task Force recommendation regarding re-administration of streptokinase

Michael Thimme*

Aventis Behring GmbH, P.O. Box 1230, D 35002 Marburg, Germany

* Corresponding author: Tel.: +49-6421-39-12; fax: +49-6421-39-4941; www.AventisBehring.com
E-mail address: michael.thimme@aventis.com

Received 3 March 2003; revised 3 March 2003; accepted 31 March 2003

The first 10% of the full text of this article appears below.

Dear Sir

In the recently published Task force report, under section ‘Fibrinolytic regimens’, the authors recommend not to re-administer streptokinase for at least 10 years. The reference supporting this statement is Ref. 51. After evaluating this paper and looking into the literature my comments . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?